Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-18P encodes a pseudogene related to the small nuclear RNA U2 family, part of a group of genes derived from functional U2 snRNA sequences. While U2 snRNA is a key RNA component of the spliceosome required for mRNA precursor splicing, pseudogenes like RNU2-18P typically arise from duplication or mutation of functional snRNA genes and do not produce active molecules or functional protein products. RNU2-18P is not known to be involved in any biological regulatory mechanism, disease association, or therapeutic targeting and is not considered a functional gene coding for active snRNA or any other biomolecule. This gene is not considered a therapeutic target, enzyme, transporter, receptor, or member of a druggable family. The "is_incorrect" entry is set to true because pseudogenes such as RNU2-18P are not typically considered biological targets with functional relevance, and no evidence links this gene to disease processes, drugs, biomarkers, or therapeutic safety challenges. No evidence exists that this pseudogene is involved in signal transduction, cell cycle, apoptosis, immune response, or any other canonical biological function. If the functional U2 snRNA is intended, reference should shift to the active U2 snRNA genes (e.g., RNU2-1, RNU2), which participate in splicing as part of the spliceosome. RNU2-18P is best classified as a member of the noncoding RNA pseudogene family associated with the U2 small nuclear RNAs rather than as a separate molecular target or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 18, pseudogene (RNU2-18P).